source
- LifeMine secures $263M to advance fungal-derived organ transplant drugLifeMine Therapeutics announced it has closed two venture financings that together raised $263 million. The capital will be used to push its experimental therapy, LIFE-001, further along the develo…
- Tarsus to acquire Alkeus for $450 million, adding phase-3 retinal drug and oral Stargardt candidateTarsus Pharmaceuticals announced it will buy Alkeus Pharmaceuticals in a transaction valued at $450 million. The deal consists of $270 million in cash and $180 million of Tarsus common stock, givi…